Dr. Lombard received his MD from Harvard Medical School, and his PhD at MIT, where he studied Werner syndrome and related premature aging diseases. After Pathology residency at the Brigham and Women’s Hospital in Boston, Dr. Lombard pursued postdoctoral work in the area of sirtuin biology, supported by an NIA/NIH K08 award. Dr. Lombard was the first to describe a central role for the sirtuin SIRT3 in regulating mitochondrial protein acetylation. He set up his independent lab at the University of Michigan in 2008, where he rose to the rank of tenured Associate Professor, and directed the T32-supported Cancer Biology doctoral program. Dr. Lombard’s research interests focus on the interrelationships between cancer, aging, and metabolism. He was named a New Scholar in Aging of the Ellison Medical Foundation, a member of The American Society for Clinical Investigation, a Scholar-Innovator of the Harrington Discovery Institute, and a recipient of an AACR Innovation and Discovery award. He serves a member of many NIH, DoD, and foundation review panels. Dr. Lombard joined the faculty of the Miller School of Medicine and the Sylvester Comprehensive Cancer Center in the spring of 2022. He serves as Vice-Chair for Clinical and Translational Research in the Department of Pathology & Laboratory Medicine, and Co-Leader of the Cancer Epigenetics program at the Sylvester.